Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : BRI2TCBDR009
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 56.84 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.15 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 29.02 | |||||
Beneish M-Score | 90.8 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 147 | |||||
3-Year EBITDA Growth Rate | 20.3 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 26.5 | |||||
3-Year Book Growth Rate | -9.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 44.27 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.25 | |||||
9-Day RSI | 61.09 | |||||
14-Day RSI | 72.94 | |||||
6-1 Month Momentum % | 68.3 | |||||
12-1 Month Momentum % | 68.3 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.66 | |||||
Quick Ratio | 7.51 | |||||
Cash Ratio | 6.06 | |||||
Days Inventory | 176.4 | |||||
Days Sales Outstanding | 76.14 | |||||
Days Payable | 94.97 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.29 | |||||
Operating Margin % | -19.85 | |||||
Net Margin % | -14.1 | |||||
FCF Margin % | -10.11 | |||||
ROE % | -10.58 | |||||
ROA % | -8.93 | |||||
ROIC % | -77.81 | |||||
ROC (Joel Greenblatt) % | -120.12 | |||||
ROCE % | -14.66 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 38.77 | |||||
PS Ratio | 13.74 | |||||
PB Ratio | 7.72 | |||||
Price-to-Tangible-Book | 7.72 | |||||
EV-to-EBIT | -63.63 | |||||
EV-to-Forward-EBIT | 175.27 | |||||
EV-to-EBITDA | -63.91 | |||||
EV-to-Forward-EBITDA | -692.26 | |||||
EV-to-Revenue | 12.63 | |||||
EV-to-Forward-Revenue | 8.24 | |||||
EV-to-FCF | -126.33 | |||||
Price-to-Net-Current-Asset-Value | 8.1 | |||||
Price-to-Net-Cash | 10.69 | |||||
Earnings Yield (Greenblatt) % | -1.57 | |||||
FCF Yield % | -0.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 3,204.287 | ||
EPS (TTM) (R$) | -0.753 | ||
Beta | 0 | ||
Volatility % | 36.92 | ||
14-Day RSI | 72.94 | ||
14-Day ATR (R$) | 0.342941 | ||
20-Day SMA (R$) | 84.148 | ||
12-1 Month Momentum % | 68.3 | ||
52-Week Range (R$) | 49.53 - 85.98 | ||
Shares Outstanding (Mil) | 106.02 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Intra-Cellular Therapies Inc Stock Events
Event | Date | Price(R$) | ||
---|---|---|---|---|
No Event Data |
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(BSP:I2TC34)'s stock price today?
When is next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34)?
Does Intra-Cellular Therapies Inc(BSP:I2TC34) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |